Immunome Inc reports results for the quarter ended March 31 - Earnings Summary

• Immunome Inc IMNM.OQ reported a quarterly adjusted loss of 52 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-2.51. The mean expectation of nine analysts for the quarter was for a loss of 68 cents per share. Wall Street expected results to range from -89 cents to -49 cents per share.

• Revenue rose 184.4% to $2.93 million from a year ago; analysts expected $285.71 thousand.

• Immunome Inc's reported EPS for the quarter was a loss of 52 cents​.

• The company reported a quarterly loss of $41.64 million.

• Immunome Inc shares had risen by 10.8% this quarter and lost 29.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Immunome Inc is $23.00

This summary was machine generated from LSEG data May 12 at 08:53 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)